215 related articles for article (PubMed ID: 32172199)
21. Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints.
Saad ED; Buyse M
Curr Opin Oncol; 2020 Jul; 32(4):384-390. PubMed ID: 32541329
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and consensus definitions for the Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes.
Beattie WS; Lalu M; Bocock M; Feng S; Wijeysundera DN; Nagele P; Fleisher LA; Kurz A; Biccard B; Leslie K; Howell S; Landoni G; Grocott H; Lamy A; Richards T; Myles P; ; ; ; ; ; ; ; ; ; ; ; ; ;
Br J Anaesth; 2021 Jan; 126(1):56-66. PubMed ID: 33092804
[TBL] [Abstract][Full Text] [Related]
23. Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials.
Renfro LA; Sargent DJ
Chin Clin Oncol; 2016 Dec; 5(6):80. PubMed ID: 28061544
[TBL] [Abstract][Full Text] [Related]
24. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: renal endpoints.
McIlroy DR; Bellomo R; Billings FT; Karkouti K; Prowle JR; Shaw AD; Myles PS
Br J Anaesth; 2018 Nov; 121(5):1013-1024. PubMed ID: 30336845
[TBL] [Abstract][Full Text] [Related]
25. Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.
Moossdorff M; van Roozendaal LM; Strobbe LJ; Aebi S; Cameron DA; Dixon JM; Giuliano AE; Haffty BG; Hickey BE; Hudis CA; Klimberg VS; Koczwara B; Kühn T; Lippman ME; Lucci A; Piccart M; Smith BD; Tjan-Heijnen VC; van de Velde CJ; Van Zee KJ; Vermorken JB; Viale G; Voogd AC; Wapnir IL; White JR; Smidt ML
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381395
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
[TBL] [Abstract][Full Text] [Related]
27. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
28. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.
van de Velde CJ; Boelens PG; Borras JM; Coebergh JW; Cervantes A; Blomqvist L; Beets-Tan RG; van den Broek CB; Brown G; Van Cutsem E; Espin E; Haustermans K; Glimelius B; Iversen LH; van Krieken JH; Marijnen CA; Henning G; Gore-Booth J; Meldolesi E; Mroczkowski P; Nagtegaal I; Naredi P; Ortiz H; Påhlman L; Quirke P; Rödel C; Roth A; Rutten H; Schmoll HJ; Smith JJ; Tanis PJ; Taylor C; Wibe A; Wiggers T; Gambacorta MA; Aristei C; Valentini V
Eur J Cancer; 2014 Jan; 50(1):1.e1-1.e34. PubMed ID: 24183379
[TBL] [Abstract][Full Text] [Related]
29. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
30. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 Dec; 26(12):2505-6. PubMed ID: 26467471
[No Abstract] [Full Text] [Related]
31. Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.
Fiteni F; Paillard MJ; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 Feb; 17(2):167-173. PubMed ID: 27937067
[TBL] [Abstract][Full Text] [Related]
32. Supportive care for patients with gastrointestinal cancer.
Ahmed N; Ahmedzai S; Vora V; Hillam S; Paz S
Cochrane Database Syst Rev; 2004; 2004(3):CD003445. PubMed ID: 15266485
[TBL] [Abstract][Full Text] [Related]
33. Antigen-specific active immunotherapy for ovarian cancer.
Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
[TBL] [Abstract][Full Text] [Related]
34. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
Gill S; Sargent D
Oncologist; 2006 Jun; 11(6):624-9. PubMed ID: 16794241
[TBL] [Abstract][Full Text] [Related]
35. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
36. Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).
Butcher NJ; Monsour A; Mew EJ; Szatmari P; Pierro A; Kelly LE; Farid-Kapadia M; Chee-A-Tow A; Saeed L; Monga S; Ungar W; Terwee CB; Vohra S; Fergusson D; Askie LM; Williamson PR; Chan AW; Moher D; Offringa M
Trials; 2019 Mar; 20(1):161. PubMed ID: 30841935
[TBL] [Abstract][Full Text] [Related]
37. End points in heart failure-are we doing it right?
Goenka L; George M; Selvarajan S
Eur J Clin Pharmacol; 2017 Jun; 73(6):651-659. PubMed ID: 28280889
[TBL] [Abstract][Full Text] [Related]
38. Systematic review and consensus definitions for standardised endpoints in perioperative medicine: postoperative cancer outcomes.
Buggy DJ; Freeman J; Johnson MZ; Leslie K; Riedel B; Sessler DI; Kurz A; Gottumukkala V; Short T; Pace N; Myles PS;
Br J Anaesth; 2018 Jul; 121(1):38-44. PubMed ID: 29935592
[TBL] [Abstract][Full Text] [Related]
39. Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set.
Heppt MV; Steeb T; Schmitz L; Garbe C; French LE; Leiter U; Berking C
Trials; 2019 Oct; 20(1):589. PubMed ID: 31604473
[TBL] [Abstract][Full Text] [Related]
40. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
